During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting.

She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma (RCC), where delay of 3 months did not have an increased risk of tumour progression. She also talks about adjuvant therapy for locally advanced RCC, predictive biomarkers and new treatments for metastatic RCC, such as MK-6482, a HIF-2α inhibitor that is in phase 3 clinical trials, and a glutaminase inhibitor (telaglenastat) that has promising data in combination with everolimus.

Read more in Cancer Therapy Advisor here